top of page
Search

Akthelia Pharma at the International Bio Convention #BIO2025

  • Writer: Akthelia News Desk
    Akthelia News Desk
  • Jun 16
  • 2 min read

REYKJAVIK, Iceland -- June 16, 2025 -- Akthelia Pharmaceuticals is thrilled to be at the International Bio Convention in Boston this week in Boston to present our pioneering work towards safer and more effective cancer therapies. Come and meet us at #BIO2025


Akthelia Pharmaceuticals is attending the International Bio Convention with a clear objective to connect with potential partners and investors to secure $25 million needed to fund the company through to the end of Phase IIA proof-of-concept (POC) for AKT-011.


The immediate focus is on raising the first tranche of $3 million to complete final preclinical studies and initiate Phase I clinical trials, a critical step toward validating the drug’s potential as a first-in-class therapy for gastrointestinal mucositis (CIGM). This convention provides a prime opportunity to showcase AKT-011’s robust preclinical data and market potential, engaging with industry leaders to build strategic alliances and secure the initial funding to drive this potentially transformative asset forward and address the urgent need for innovative treatments in oncology and beyond.



ABOUT AKTHELIA PHARMACEUTICALS


Akthelia Pharmaceuticals is a pioneering biopharmaceutical company, focusing on therapeutics that target mucosal barrier injury and epithelial integrity, via a novel biology-driven immunotherapeutic strategy that upregulates epithelial surfaces.


Akthelia's lead program is a late preclinical stage asset with potential to be a first-in-class oral therapeutic addressing the large unmet need to improve cancer care outcomes by reducing the risk of mucositis which leads to a range of serious complications, including chemotherapy-induced bloodstream infection and febrile neutropenia, with a high mortality rate. Akthelia's platform also addresses the urgent global threat of antibiotic bacterial resistance (AMR).


CONTACTS

Akthelia Pharmaceuticals Grandagardi 16 101 Reykjavik Iceland

bottom of page